COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 26 FDA records to the applicant name Siemens Healthcare Diagnostics, Inc.. The collection includes 6 510(k) clearances. It includes 4 original PMA approvals. 7 entries are PMA supplements. 9 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 15, 1995 to Nov 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MTF appears in 9 of the 26 linked filings. The collection spans 10 FDA product codes and 8 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P930027, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 511 Benedict Ave., Tarrytown, NY, 10591, US. Recorded on K260674, decision dated Nov 6, 2026.
Device categories in this collection
System, Test, Vitamin D; Kit, Test, Alpha-Fetoprotein For Neural Tube Defects; Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer; System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer; Colorimetry, Acetaminophen; Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions.
Changes described in PMA records
The FDA record for P010007/S028, under the title IMMULITE Systems AFP with decision OK30 dated 2026-09-22, is a 30-Day Notice whose supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The stated change is to move manufacturing of a critical component within the same facility. The notice does not describe the component, its function, the affected manufacturing steps, or any validation or comparability data supporting the move.
The identifier P010007 ties this supplement to the original PMA for an alpha-fetoprotein kit for neural tube defects, product code LOK, with Siemens Healthcare Diagnostics, Inc. as applicant. It is a supplement notice concerning a manufacturing location change, not a new approval of the whole system, and the reported purpose does not by itself establish safety or clinical effectiveness. The record is silent on whether analytical performance or previously cleared indications are affected.
FDA approval-order wording
to move manufacturing of a critical component within the same facility
Sep 22, 2026 · 30-Day NoticeThe FDA record for P930027/S041 lists a 30-day notice for IMMULITE Systems PSA, with the stated purpose of moving manufacturing of a critical component within the same facility. The notice reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The record does not name the component, the facility, or the manufacturing steps involved, so the scope of the change cannot be described beyond the field labels.
The identifier ties this supplement to the original PMA P930027, which covers total prostate specific antigen testing for detection of prostate cancer under product code MTF in Immunology, submitted by Siemens Healthcare Diagnostics, Inc. A supplement is not a new approval of the whole system, and a manufacturing notice is not an original PMA. The reported purpose of the move does not by itself establish safety or clinical effectiveness.
FDA approval-order wording
to move manufacturing of a critical component within the same facility
Sep 22, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica CI Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
Aug 26, 2026 · Normal 180 Day TrackFDA’s recorded scope: Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.
Aug 20, 2026 · 30-Day NoticeFDA’s recorded scope: Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.
Aug 20, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.